UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 364

Sortiert nach

Gastrointestinal side effects in chronic opioid users: results from a population‐based survey

Alimentary pharmacology & therapeutics, 2008-06, Vol.27 (12), p.1224-1232

2008

Volltextzugriff (PDF)

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study

Alimentary pharmacology & therapeutics, 2010-11, Vol.32 (9), p.1102-1112

2010

Volltextzugriff (PDF)

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

The Lancet (British edition), 2000-03, Vol.355 (9209), p.1035-1040

2000

Volltextzugriff (PDF)

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome

Alimentary pharmacology & therapeutics, 2008-07, Vol.28 (2), p.239-249

2008

Volltextzugriff (PDF)

Prevalence and demographics of irritable bowel syndrome: results from a large web‐based survey

Alimentary pharmacology & therapeutics, 2005-11, Vol.22 (10), p.935-942

2005

Volltextzugriff (PDF)

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist

Alimentary pharmacology & therapeutics, 1999-09, Vol.13 (9), p.1149-1159

1999

Volltextzugriff (PDF)

Clinical trial: dextofisopam in the treatment of patients with diarrhoea‐predominant or alternating irritable bowel syndrome

Alimentary pharmacology & therapeutics, 2008-01, Vol.27 (2), p.197-206

2008

Volltextzugriff (PDF)

Determinants of healthcare‐seeking behaviour among subjects with irritable bowel syndrome

Alimentary pharmacology & therapeutics, 2006-06, Vol.23 (11), p.1667-1675

2006

Volltextzugriff (PDF)

Personal view: adequate relief as a primary endpoint in irritable bowel syndrome

Alimentary pharmacology & therapeutics, 2006-04, Vol.23 (7), p.879-881

MANGEL, A. W.

2006

Volltextzugriff (PDF)

A dose‐ranging, placebo‐controlled, randomized trial of alosetron in patients with functional dyspepsia

Alimentary pharmacology & therapeutics, 2001-04, Vol.15 (4), p.525-537

2001

Volltextzugriff (PDF)

Stability of irritable bowel syndrome using a Rome II‐based classification

Alimentary pharmacology & therapeutics, 2006-01, Vol.23 (1), p.197-205

2006

Volltextzugriff (PDF)

Study design issues in irritable bowel syndrome

Alimentary pharmacology & therapeutics, 2004-01, Vol.19 (1), p.141-142

Mangel, A. W.

2004

Volltextzugriff (PDF)

Adequate relief as an endpoint in clinical trials in irritable bowel syndrome

Journal of international medical research, 1998-03, Vol.26 (2), p.76

1998

Volltextzugriff (PDF)

Global endpoints in functional gastrointestinal disease

Alimentary pharmacology & therapeutics, 2005-12, Vol.22 (11‐12), p.1162-1163

2005

Volltextzugriff (PDF)

Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists

Neurogastroenterology and motility, 2008-10, Vol.20 (10), p.1086-1093

2008

Volltextzugriff (PDF)

Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist

Digestive diseases and sciences, 1999, Vol.44 (1), p.20-24

1999

Volltextzugriff (PDF)

Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome

Alimentary pharmacology & therapeutics, 1997-12, Vol.11 (6), p.1073-1076

1997

Volltextzugriff (PDF)

Adenosine triphosphate activates ion permeabilities in biliary epithelial cells

Gastroenterology (New York, N.Y. 1943), 1994-07, Vol.107 (1), p.236-243

1994

Volltextzugriff (PDF)

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria

The American journal of gastroenterology, 1999-05, Vol.94 (5), p.1279-1282

1999

Volltextzugriff (PDF)

Nucleotide receptors regulate membrane ion transport in renal epithelial cells

American journal of physiology. Renal physiology, 1993-05, Vol.264 (5), p.867-F873

1993

Volltextzugriff (PDF)

Cl− and K+ transport in human biliary cell lines

Gastroenterology (New York, N.Y. 1943), 1993-06, Vol.104 (6), p.1796-1805

1993

Volltextzugriff (PDF)

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

The American journal of gastroenterology, 2001-02, Vol.96 (2), p.455-459

2001

Volltextzugriff (PDF)

Review article: the safety and efficacy of alosetron, a 5‐HT3 receptor antagonist, in female irritable bowel syndrome patients

Alimentary pharmacology & therapeutics, 1999-05, Vol.13, p.77-82

1999

Volltextzugriff (PDF)

Regulation of high-conductance anion channels by G proteins and 5-HT1A receptors in CHO cells

American journal of physiology. Renal physiology, 1993-03, Vol.264 (3), p.490-F495

1993

Volltextzugriff (PDF)

Regulation of cholecystokinin secretion by bombesin in STC-1 cells

American journal of physiology: Gastrointestinal and liver physiology, 1994-11, Vol.267 (5 Pt 1), p.G859-G865

1994

Volltextzugriff (PDF)

1 – 25 von 364

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(320)
Mit Volltextzugriff
(317)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(363)
Japanisch
(24)
Deutsch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(214)
Life Sciences & Biomedicine
(194)
Humans
(99)
Biological And Medical Sciences
(81)
Animals
(78)
Biochemistry & Molecular Biology
(65)
Fundamental And Applied Biological Sciences. Psychology
(49)
Gastroenterology & Hepatology
(42)
Female
(41)
Kinetics
(40)
Male
(33)
Medical Sciences
(32)
Pharmacology & Pharmacy
(31)
Pharmacology. Drug Treatments
(26)
Adult
(24)
Middle Aged
(24)
Amino Acid Sequence
(22)
Mice
(21)
Physiology
(21)
Binding Sites
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Gastrointestinal side effects in chronic opioid users: results from a population‐based survey

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome

Prevalence and demographics of irritable bowel syndrome: results from a large web‐based survey

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist

Clinical trial: dextofisopam in the treatment of patients with diarrhoea‐predominant or alternating irritable bowel syndrome

Determinants of healthcare‐seeking behaviour among subjects with irritable bowel syndrome

Personal view: adequate relief as a primary endpoint in irritable bowel syndrome

A dose‐ranging, placebo‐controlled, randomized trial of alosetron in patients with functional dyspepsia

Stability of irritable bowel syndrome using a Rome II‐based classification

Study design issues in irritable bowel syndrome

Adequate relief as an endpoint in clinical trials in irritable bowel syndrome

Global endpoints in functional gastrointestinal disease

Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists

Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist

Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome

Adenosine triphosphate activates ion permeabilities in biliary epithelial cells

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria

Nucleotide receptors regulate membrane ion transport in renal epithelial cells

Cl− and K+ transport in human biliary cell lines

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

Review article: the safety and efficacy of alosetron, a 5‐HT3 receptor antagonist, in female irritable bowel syndrome patients

Regulation of high-conductance anion channels by G proteins and 5-HT1A receptors in CHO cells

Regulation of cholecystokinin secretion by bombesin in STC-1 cells

Suchergebnisse filtern